Search Results
Jul 13, 2026, 08:00 ET Payoneer Expands India Presence with New Gurugram Innovation Hub
Strategic investment positions India as both growth market and critical R&D center for AI-powered fintech transformation GURUGRAM, India, July 13, 2026 /PRNewswire/ --
More news about: Payoneer
Jul 13, 2026, 07:30 ET Curaleaf First to Secure Registration for Standardized Cannabis Preparations in Spain
life.The registrations build on Curaleaf's long-established presence in Spain, where the Company operates an EU-GMP certified manufacturing facility and R&D laboratory in Alicante. In May 2020, Curaleaf's EU-GMP laboratory, Medalchemy SL, secured the first-ever license granted by AEMPS to process medicinal
More news about: Curaleaf Holdings, Inc.
Jul 13, 2026, 07:30 ET Keenova Announces Publication of New Acthar® Gel (repository corticotropin injection) Manuscript in the Journal of Comparative Effectiveness Research
dermatomyositis/polymyositis: Analysis of physician-reported chartsAuthors: Kyle Hayes, MS; Amit Patel, PhD; Priyanka P. Shanbhag, MS; Destri R. Evans, MBA; Mary Prince Panaccio, PhD; Johanna Purcell, PhD; George J. Wan, PhD, MPHAbout Rheumatoid ArthritisRheumatoid
More news about: Keenova Therapeutics
Jul 13, 2026, 07:12 ET ESGFIRE Publishes Pre-Listing Analysis on Alchemy Labs Inc. (TSXV: ALCH) Ahead of TSX Venture Exchange Debut
https://news.cision.com/esgfire/r/esgfire-publishes-pre-listing-analysis-on-alchemy-labs-inc---tsxv--alch--ahead-of-tsx-venture-exchan,c4374128
More news about: ESGFIRE
Jul 13, 2026, 07:07 ET Cochlear introduces the new Osia® 3 Sound Processor
3(I) Sound Processor and OSI300 Implant Datasheet. Cochlear Limited, Sweden. 2026; D2304776.BCI602 BONEBRIDGE System Factsheet. Med-El. 29214 r4.0Sentio 1 Mini Product Information. Oticon Medical. 275144en – Version A / 2024.0Cochlear Limited. D2304775-V1_EN Osia 3 SP and OSI200
More news about: Cochlear North America
Jul 13, 2026, 06:02 ET Nammos Hotels & Resorts i Smokva Bay wspólnie stworzą w Czarnogórze wyjątkowy kompleks inspirowany śródziemnomorskim stylem życia
PODGORICA, Czarnogóra, 13 lipca 2026 r. /PRNewswire/ -- Nammos Hotels & Resorts i Smokva Bay ogłosiły nawiązanie współpracy w celu realizacji Nammos Resort Montenegro - w pełni zintegrowanego, luksusowego obiektu wypoczynkowego
More news about: Nammos Hotels and Resorts
Jul 13, 2026, 05:49 ET Advancing Low-Carbon Manufacturing and Global Sustainability Commitments
Growth Through InnovationInnovation remained central to INTCO Medical's sustainability strategy. In 2025, the Company continued to invest in R&D, product upgrades and intelligent manufacturing, while advancing its core business segments: medical consumables, rehabilitation medical equipment
More news about: INTCO Medical
Jul 13, 2026, 05:30 ET INDIANA UNIVERSITY AND PHARMATROPHIX PRESENT FINDINGS ON PERFORMANCE OF ORAL THERAPEUTIC, LM11A-31, TO REDUCE DECLINE OF BRAIN FUNCTIONAL-NETWORK CONNECTIVITY IN ALZHEIMER'S DISEASE
therapeutic effects in neurodegenerative disorders that are particularly relevant to cognitive function.The Indiana University research team led by Paul R. Territo, PhD, and Juan Antonio Chong Chie, PhD, processed 18F-FDG-PET scan data from 159 participants in the Phase 2a trial of LM11A-31 with mild to
More news about: PharmatrophiX
Jul 13, 2026, 05:19 ET Advancing Low-Carbon Manufacturing and Global Sustainability Commitments
Growth Through InnovationInnovation remained central to INTCO Medical's sustainability strategy. In 2025, the Company continued to invest in R&D, product upgrades and intelligent manufacturing, while advancing its core business segments: medical consumables, rehabilitation medical equipment
More news about: INTCO Medical
Jul 13, 2026, 04:56 ET Leads Biolabs Announces Multiple Studies Selected for ESMO 2026, Highlighting the Growing Global Competitiveness of Its Core Pipeline
clinical-stage drug candidates and one registration-stage asset.The Company adopts a science-driven R&D approach and has successfully established comprehensive R&D capabilities spanning antibody discovery and engineering, in vivo and in vitro efficacy evaluation, as well as druggability
More news about: Leads Biolabs
Jul 13, 2026, 04:00 ET Lighthouse Pharmaceuticals Reports New Evidence that Gingipain Inhibition Benefits Neuropsychiatric Symptoms and Reduces Caregiver Distress in P. gingivalis-Positive Alzheimer's Disease at AAIC 2026
www.lighthousepharma.com.The SPRING trial is supported by the National Institute on Aging of the National Institutes of Health under Award Number R01AG088524. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Media
More news about: Lighthouse Pharmaceuticals
Jul 13, 2026, 03:30 ET Tomocube Launches HT-T1 Desktop for 3D Glass Substrate Defect Analysis in Advanced Packaging
morphology, and depth profile of internal defects in glass substratesIntroduces TAMI, a dedicated 3D analysis software platform that connects R&D analysis with production-line reviewAccelerates root-cause analysis and yield learning for glass substrates, a key material for next-generation
More news about: Tomocube
Jul 13, 2026, 03:30 ET Tomocube lance le HT-T1 Desktop pour l'analyse 3D des défauts des substrats de verre dans le conditionnement avancé
profondeur des défauts internes dans les substrats de verre.Présente TAMI, une plateforme logicielle dédiée à l'analyse 3D qui relie l'analyse R&D à l'inspection directement sur la ligne de production.Accélère l'analyse des causes profondes et l'optimisation du rendement (yield learning)
More news about: Tomocube
Jul 13, 2026, 03:29 ET Gentoo Media appoints Måns Svalborn as Chief Financial Officer
https://news.cision.com/gentoo-media-inc/r/gentoo-media-appoints-mans-svalborn-as-chief-financial-officer,c4373661
More news about: Gentoo Media Inc
Jul 13, 2026, 03:27 ET Gentoo Media appoints Måns Svalborn as Chief Financial Officer
https://news.cision.com/gentoo-media-inc/r/gentoo-media-appoints-mans-svalborn-as-chief-financial-officer,c4373661
More news about: Gentoo Media Inc
Jul 13, 2026, 03:04 ET Share buybacks in Ericsson during the period July 6 - July 10, 2026
https://news.cision.com/ericsson/r/share-buybacks-in-ericsson-during-the-period-july-6---july-10--2026,c4373890The following files are available for download:
More news about: Ericsson
Jul 13, 2026, 03:02 ET Sectra achieves the highest level of security attestation for healthcare providers adopting cloud services in Germany
https://news.cision.com/sectra/r/sectra-achieves-the-highest-level-of-security-attestation-for-healthcare-providers-adopting-cloud-se,c4371924The following files are available for download:
More news about: Sectra
Jul 13, 2026, 02:58 ET Share buybacks in Ericsson during the period July 6 - July 10, 2026
https://news.cision.com/ericsson/r/share-buybacks-in-ericsson-during-the-period-july-6---july-10--2026,c4373890The following files are available for download:
More news about: Ericsson
Jul 13, 2026, 01:22 ET Sivers Board Completes Purchase of Shares as Approved at the June 2026 AGM
https://news.cision.com/sivers-semiconductors/r/sivers-board-completes-purchase-of-shares-as-approved-at-the-june-2026-agm,c4373923
More news about: Sivers Semiconductors
Jul 13, 2026, 00:08 ET New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease
https://news.cision.com/bioarctic/r/new-clinical-data-on-the-leqembi--subcutaneous-autoinjector-presented-at-aaic--2026-support-similar-,c4373863The following files are available for download:
More news about: BioArctic
Jul 13, 2026, 00:02 ET New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease
https://news.cision.com/bioarctic/r/new-clinical-data-on-the-leqembi--subcutaneous-autoinjector-presented-at-aaic--2026-support-similar-,c4373863The following files are available for download:
More news about: BioArctic
Jul 13, 2026, 00:00 ET Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB
royalties on future net sales.About Antengene Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs.
More news about: Antengene Corporation Limited
Jul 12, 2026, 20:30 ET Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases
agreement, the two parties will jointly advance the co-development of the R&D program by combining Insilico Medicine's validated AI platform and AI-enabled innovative drug discovery and development capabilities with CMS's experienced R&D team and deep therapeutic expertise. Insilico Medicine is eligible
More news about: Insilico Medicine
Jul 12, 2026, 18:00 ET PMET Demonstrates >97% Caesium Extraction from Pollucite Concentrate
using Koch's proprietary flow sheet.PMET Resources Inc. (the "Company" or "PMET") (TSX: PMET) (ASX: PMT) (OTCQX: PMETF) (FSE: R9GA) is pleased to provide an update on two parallel bench-scale testwork programs focused on caesium (Cs) extraction from pollucite samples from the Shaakichiuwaanaan
More news about: PMET Resources Inc.
Jul 12, 2026, 11:15 ET LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference® (AAIC®) 2026
Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet
More news about: Eisai Inc.